ORYX GTL Limited, a gas-to-liquids (GTL) diesel and naphtha producer, needed a new propane unit design that would incorporate a blowdown system to discharge hydrocarbon liquid under potential fire scenarios.

Keeping process safety documentation up-to-date is essential design and operations of safety devices. This video showcases how activated datasheets are created and used inside the AspenTech process simulation safety analysis environment to create reliable documentation that's updated with the latest PRD designs.

Receive the AspenTech monthly webinars e-newsletter to stay up-to-date on the latest topics for industrial leaders, including:

Leading chemical companies across the globe face more competitive pressures with volatile market conditions and a rapidly changing workforce pushing the demand for increased sustainability and profitability. Digital twin software offers new levels of operational excellence through enterprise-wide insights that drive improved business operations.

The pandemic heightened the need for agility and resiliency within the supply chain. Speed to market remains a top business imperative as we move into the next normal for pharma.

世界中で、主要な組織が高度なデジタル技術を採用および実装しています。デジタルトランスフォーメーションの旅は、資産集約型産業、特にエネルギーおよび化学薬品ビジネスの性質を変えるでしょう。こうした状況下では、デジタルツイン（物理的な資産の仮想化されたコピーとその運用上の動作）が重要な役割を果たします。今日アスペンテックが描くデジタルツインの重要なコンセプトは、仮想データに対して洞察とアドバイスを提供するAIの力です。本ホワイトペーパーでは、これからのデジタルツイン戦略で重要になる鍵をご覧いただけます。

AspenTech provides AI-enabled digital solutions that help customers optimize outcomes across the pharma value chain network using a holistic approach to digital transformation in an ever-changing world. Learn how our approach ensures the security of supply and pushes the boundaries and limits of what is possible for optimization, multiplying performance gains from digital transformation in this video.

The COVID-19 pandemic highlighted the need for agility and resiliency within the supply chain for pharmaceutical companies. It is clear that speed to market will remain a top business imperative as we move into the next normal for pharma.

The ability of bio-pharmaceutical manufacturers to deliver quality drug products during challenging market conditions is critical for ensuring sustainability over the long run. The COVID-19 pandemic underscored the need to transform the traditional bio-pharmaceutical supply chain to have greater agility and resiliency during market swings and periods of volatility.

Unnecessary downtime can be expensive for pharmaceutical manufacturing operations; unplanned stoppages can delay the delivery of much needed product, potentially causing damage to a company's reputation.